Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Inlexzo
Synonyms :
Gemcitabine intravesical
Class :
Antineoplastics, Antimetabolites
Brand Name :
Inlexzo
Synonyms :
Gemcitabine intravesical
Class :
Antineoplastics, Antimetabolites
Adult
Dosage Forms & Strengths
Single dose intravesical
225 mg
Administer dose of 225 mg intravesically for one time every 3 weeks up to 6 months Then administer for one time every 12 weeks up to 18 months
Safety and efficacy not recommended
Refer to the adult dosing
Gemcitabine is released gradually by Inlexzo to disrupts DNA synthesis and kills bladder cancer cells.
It becomes integrated into DNA itself after being transformed into active forms that prevent enzymes required for DNA building blocks.
The efficacy of gemcitabine is increased by this dual effect. It enters DNA, where it prevents more DNA synthesis and causes cancer cells to die.
Frequency defined
≥15%:
Increased creatinine
Increased potassium
Elevated liver enzymes
Urinary frequency
Increased lipase
Urinary tract pain
Decreased lymphocytes
Urinary tract infection
Dysuria
Urinary urgency
Decreased hemoglobin
Hematuria
None
Contraindications
Suffer from a bladder rip or perforation
Had an allergic response to gemcitabine or any of the components in Inlexzo
Cautions
Are pregnant, or plan to become pregnant
Breastfeeding
Kidney impairment
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion in human breastmilk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
It prevents DNA synthesis by blocking ribonucleotide reductase, which is exclusive to the cell cycle’s S-phase.
It is converted to triphosphate (dFdCTP) and diphosphate (dFdCDP) nucleosides by nucleoside kinases.
Deoxynucleotide concentrations, particularly dCTP, decrease because of gemcitabine diphosphate’s inhibition of ribonucleotide reductase.
Pharmacodynamics:
Gemcitabine triphosphate and dCTP fight for DNA incorporation.
While gemcitabine triphosphate is more readily incorporated into DNA when the intracellular quantity of dCTP is decreased.
Pharmacokinetics:
Limited information available on ADME.
A bladder medication delivery device called Inlexzo is implanted during an outpatient appointment.
Gemcitabine chemotherapy is gently released into the bladder tissue through the device, which remains in the bladder for three weeks.
Each three-week therapy cycle might last up to 14 cycles for patients.
Generic Name: gemcitabine intravesical
Why do we use gemcitabine intravesical?
Gemcitabine intravesical is recently approved FDA drug indicated in the treatment of bladder cancer.
Adults with non-muscle invasive bladder cancer (NMIBC) who did not react to BCG treatment and whose disease has not migrated to other areas of their body are treated with Inlexzo.
The bladder cancer cells get targeted gemcitabine treatment directly from our novel intravesical medication delivery device.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
